Dov Zippel

General Surgeon | Surgical Oncologist | Breast & Melanoma Specialist

Forbes Israel’s “Best Doctors” list (2025)

Areas of Expertise

Professor Dov Zippel specializes in surgical oncology, with a particular focus on breast diseases and skin malignancies:

Breast Cancer

Advanced surgical treatment of malignant breast tumors

Breast Tumors (Benign & Malignant)

Modern minimally invasive and organ-preserving surgical approaches

Melanoma

Surgical management of early and advanced-stage melanoma

Skin Cancer

Comprehensive surgical treatment of various skin malignancies

General Surgery

Wide range of surgical procedures with oncological focus

About the Doctor

Professor Dov Zippel is a highly experienced surgical oncologist and general surgeon, specializing in the treatment of breast cancer and melanoma.

He serves as the Head of the Meirav Breast Center at Sheba Medical Center, where he leads advanced, patient-centered care for individuals with breast diseases.

In addition, Professor Zippel is a surgical specialist at the Ella Lemelbaum Institute for Immuno-Oncology, contributing to multidisciplinary cancer treatment strategies that integrate surgery with modern systemic therapies.

His clinical approach focuses on precision surgery, optimal oncological outcomes, and preservation of quality of life, using up-to-date techniques and individualized treatment planning.

Education and Training

MD, School of Medicine, Tel Aviv University, Israel

Residency in General Surgery, Sheba Medical Center (Department of General Surgery C)

Fellowship (Sub-residency) in Surgical Oncology, University of Calgary, Canada

Board Certifications

General Surgery

Surgical Oncology

Positions

Head of the Meirav Breast Center, Sheba Medical Center

Surgical Oncologist, Ella Lemelbaum Institute for Immuno-Oncology

Research & Publications

Professor Zippel is actively involved in clinical research and has contributed to scientific publications, including:

Use of the Intact® breast lesion excision system as a therapeutic option for selected benign breast lesions

Studies on perioperative BRAF inhibitors in patients with locally advanced stage III melanoma